Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters
Trial Parameters
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of new oral anticoagulants and vitamin K antagonists for the anticoagulation for the implantation of vena cava filters in patients with deep venous thrombosis.
Eligibility Criteria
Inclusion Criteria: * Patients who was diagnosed with deep venous thrombosis of the lower extremity and implanted with a retrievable inferior vena cava filter. Exclusion Criteria: * Age \< 18 years or age \> 75 years, * With obvious contraindications for anticoagulation therapy, * Allergic to iodine contrast agents in the past, * Pregnant or breastfeeding women, * With malignant tumors and life expectancy \< 1 year, * Severe liver diseases (such as acute hepatitis, chronic active hepatitis or cirrhosis) or alanine aminotransferase levels were higher than three times the upper limit of normal. * With other diseases that need anticoagulation, * With previous heparin-induced thrombocytopenia, * Bacterial endocarditis, * Systolic blood pressure \> 180 mmHg or diastolic blood pressure \> 110 mmHg, * Taking cytochrome P450 3A4(CYP-450 3A4) inhibitors or inducers * With severe renal insufficiency (creatinine clearance \<30 mL/min) * Allergic to the drug used in this study * With permanent fil